PUBLISHER: DelveInsight | PRODUCT CODE: 1442050
PUBLISHER: DelveInsight | PRODUCT CODE: 1442050
Glaucoma Market Insight, Epidemiology And Market Forecast - 2034
Key Highlights:
- Total diagnosed prevalent cases of Glaucoma were estimated at nearly 7,045,443 cases in 2022 in the 7MM, however overall burden of Glaucoma has been estimated to be nearly 16,632,421 (Prevalent cases) in 2022 in the 7MM.
- Most diagnosed Glaucoma patients were estimated in the US, followed by Japan, Germany, and France in 2022.
- Open Angle Glaucoma is most prominent type of Glaucoma with high burden in the 7MM.
- As per DelveInsight estimations, the US consistently captured the highest market size with USD 2,571 million net sales revenue in 2022 among the 7MM, whereas the UK had the lowest market with a market size of nearly USD 132 million.
- The current treatment market for Glaucoma includes Prostaglandin analogs, beta-blockers, carbonic anhydrase inhibitors, fixed Combinations, alpha-2-selective adrenergic agonists, and Others.
- The total market size of the Glaucoma is anticipated to upsurge during the forecast period due to the expected entry of emerging therapies that includes iDose TR (travoprost intraocular implant), NCX 470, PDP-71, and others.
DelveInsight's "Glaucoma - Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Glaucoma, historical and forecasted epidemiology and the Glaucoma market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The Glaucoma market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM, Glaucoma market size from 2020 to 2034. The report also covers current Glaucoma treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Geography Covered:
- The United States
- EU4 (Germany, France, Italy, and Spain) and the United Kingdom
- Japan
Study Period: 2020-2034
Disease Understanding and Treatment Algorithm
Glaucoma Overview
According to the American Academy of Ophthalmology, glaucoma describes a group of conditions in which there is characteristic cupping of the optic disc with corresponding visual field defects due to retinal ganglion cell loss. It is a progressive condition and the most common cause of irreversible blindness worldwide. The two major categories of glaucoma are open-angle glaucoma (OAG) and narrow-angle glaucoma/angle-closure glaucoma (ACG). Glaucoma often does not cause noticeable symptoms in the early stages, so it is often called the "silent thief of sight." As the condition progresses, peripheral (side) vision may be affected, gradually narrowing the visual field.
Glaucoma Diagnosis
Although glaucoma is not curable, early diagnosis and adequate treatment effectively reduce or prevent further optic nerve (ON) damage. The diagnosis of glaucoma typically involves a comprehensive eye examination and several specific tests, namely, tonometry (measurement of intraocular pressure), an ophthalmoscopy (evaluation of the optic nerve for signs of damage), visual field testing (perimetry), gonioscopy (assessing the drainage angle of the eye to determine the type of glaucoma) to assess the health of the optic nerve and evaluate IOP levels.
The diagnosis of glaucoma typically involves a combination of clinical evaluation, visual field testing, optic nerve examination, and measurement of intraocular pressure (IOP). The diagnosis guidelines for glaucoma can vary to some extent based on geographical regions and medical societies, such as separate guidelines published by American Academy of Ophthalmology, European Glaucoma Society Terminology, and others.
Further details related to country-based variations are provided in the report
Glaucoma Treatment
There is no cure for glaucoma, but early treatment can often stop the damage and protect the vision. Doctors use a few different types of treatment for glaucoma, including medicines (usually eye drops), laser treatment, and surgery.
Glaucoma is treated by lowering the eye pressure (intraocular pressure), and depending on the situation, management includes prescription eye drops, oral medications, laser treatment, surgery, or a combination of any of these.
Medicines: Medications for glaucoma treatment aim to lower IOP by decreasing AH production and increasing AH outflow. Prostaglandin analogs and beta-blockers are currently the most frequently used agents.
Surgery: The most common type of surgery for glaucoma is called trabeculectomy. It involves removing part of the eye-drainage tubes to allow fluid to drain more easily.
Glaucoma Epidemiology
As the market is derived using the patient-based model, the Glaucoma epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of Glaucoma, Total Diagnosed Prevalent Cases of Glaucoma, Type-specific Diagnosed Prevalent Cases of Glaucoma, Type-specific Diagnosed Prevalent Cases of Open-angle Glaucoma, Gender-specific Diagnosed Prevalent Cases of Glaucoma, and Age-specific Diagnosed Prevalent Cases of Glaucoma in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034. The total prevalent cases of Glaucoma in the 7MM comprised approximately 16,632,421 cases in 2022 and are projected to increase during the forecast period 2023-2034.
- Glaucoma remain undetected in most of the patients due to many factors. According to DelveInsight estimations, of 16,632,421 prevalent cases in 2022 in the 7MM, only 7,045,443 cases are estimated to have received a formal diagnosis.
- The US showed the highest diagnosed prevalent population of Glaucoma compared to other 7MM countries, with nearly 2,451,089 cases in 2022. As per DelveInsight's estimates, the country alone accounts for nearly 35% of total diagnosed prevalent cases, for Glaucoma in the 7MM, followed by Japan, contributing 23% of all the Glaucoma cases.
- Glaucoma can affect both men and women, however the ratio of male to female Glaucoma patients suggest that female are predominantly affected more than males. In 2022, there were 3,234,796 cases of glaucoma among male population and 3,810,646 cases among female population.
- The diagnosed prevalent cases of glaucoma were further divided into open-angle glaucoma (OAG) and closed-angle glaucoma. The distribution showed that nearly 90% of glaucoma cases are of OAG type.
- Primary Open-Angle Glaucoma (POAG) and Secondary Open-Angle Glaucoma (SOAG) are two types of Open-angle glaucoma.
- Normal tension glaucoma (NTG) is a subtype of POAG occurring in the presence of normal IOP. As per DelveInsight's estimates, of all POAG cases in the 7MM, 52% were of NTG type.
- Among EU4 and the UK, Germany had the highest diagnosed prevalent population of glaucoma, with 701,946 cases, followed by France in 2022. On the other hand, Spain had the lowest diagnosed prevalent population of glaucoma among EU4 and the UK in 2022.
- Japan accounted for 23% of the total diagnosed prevalent cases of Glaucoma in the 7MM in 2022.
Glaucoma Drug Chapters
The drug chapter segment of the Glaucoma report encloses a detailed analysis of Glaucoma marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also understands the Glaucoma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Marketed Drugs
ROCKLATAN/ ROCLANDA (netarsudil/latanoprost, 0.02%/0.005%): Aerie Pharmaceuticals
Roclanda (in Europe), known as Rocklatan in the United States, is fixed-dose combination of a Rho kinase inhibitor and a prostaglandin F2a analog that reduces elevated intraocular pressure (IOP) in individuals diagnosed with open-angle glaucoma or hypertension. While it obtained approval in the US in March 2019, it gained approval in the European region in January 2021.
DURYSTA (bimatoprost SR): AbbVie Inc.
DURYSTA is an ophthalmic drug delivery system for a single intracameral administration of a biodegradable bimatoprost implant which is believed to lower IOP in humans by increasing the outflow of aqueous humor through both the trabecular meshwork (conventional) and uveoscleral routes (unconventional). It imitates the effects of prostamides, specifically prostaglandin F2a.
Note: Detailed marketed therapies assessment will be provided in the final report of Glaucoma.
Emerging Drugs
NCX-470: Nicox Ophthalmics
NCX 470 is an investigational ophthalmic treatment by Nicox Ophthalmics designed to address ocular hypertension and open-angle glaucoma. It belongs to the second-generation nitric oxide (NO) category-donating prostaglandin analogs. This therapeutic candidate is administered through the ophthalmic route, targeting the prostaglandin F2 alpha receptor and soluble guanylate cyclase to achieve its effects.
Based on a dual mechanism of action, NCX 470, a monotherapy, has the potential to be a new standard of care in reducing IOP glaucoma patients.
TRS01: Tarsier Pharma
TRS01, a lead product of Tarsier Pharma in Phase III, is a breakthrough immunomodulatory approach based on a bio-inspired new molecular platform. TRS was developed to engineer the immune system. The platform approaches inflammatory diseases from within the system. The technology can effectively treat various autoimmune and inflammatory ocular diseases.
Currently, TRS01 is being evaluated in a Phase III trial, called TRS4VISION, in patients with active noninfectious anterior uveitis and uveitic glaucoma. Uveitis glaucoma is a severe late-stage blinding condition that occurs when a patient develops glaucoma on top of uveitis
Note: Detailed emerging therapies assessment will be provided in the final report of Glaucoma.
Drug Class Insights
Management of the disease focuses on lowering intraocular pressure (IOP) with the current class of drugs, like prostaglandin analogs, beta-blockers, alpha-agonists, rho kinase inhibitors (ROCK) and carbonic anhydrase inhibitors. Prostaglandin analogs increase fluid outflow, beta-blockers reduce fluid production, alpha-adrenergic agonists decrease fluid production and increase outflow, carbonic anhydrase inhibitors reduce fluid production, rho kinase inhibitors increase fluid outflow, and cholinergic agonists increase fluid drainage.
The choice of medication depends on factors such as glaucoma severity, patient response, and potential side effects.
Glaucoma Market Outlook
The primary objective of disease management is to reduce intraocular pressure (IOP), typically accomplished through the use of various drug classes such as prostaglandin analogs, beta-blockers, alpha-agonists, rho kinase inhibitors (ROCK), and carbonic anhydrase inhibitors. However, not all patients benefit from these treatments, as some may still experience optic nerve deterioration despite having normal IOP levels. In addition to pharmacological interventions, alternative measures such as incisional surgery, laser surgery, and medication are also commonly recommended.
The launch of emerging therapies, such as NCX 470 (Nicox Ophthalmics), PDP-716 (Sun Pharma Advanced Research Company Limited (SPARC)/ Visiox Pharma), and others are expected to impact the market positively.
- The total market size of Glaucoma in the 7MM was around USD 4,073 million in 2022. This is estimated to increase by 2034 at a significant CAGR.
- In the 7MM, most of the market share was accommodated by prostaglandin analogs generating nearly USD 2,541 million, followed by fixed combination therapies in 2022.
- Among the 7MM, the US captured the highest market in 2022, covering a total of 63% market, followed by Japan which is anticipated to grow during the forecast period (2023-2034).
- In 2022, EU4 and the UK captured nearly 24% of the total market in the 7MM.
- Among the forecasted emerging therapies, iDose TR is expected to capture the highest market in the 7MM by 2034.
Glaucoma Drugs Uptake
This section focuses on the uptake rate of potential drugs expected to launch in the market during 2020-2034. For example, for PDP-716, in the US we expect the drug uptake to be Slow-medium with a probability-adjusted peak share of around 2%, and years to the peak is expected to be 8 years from the year of launch.
Further detailed analysis of emerging therapies drug uptake in the report.
Glaucoma Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Glaucoma emerging therapies.
KOL Views
To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Glaucoma evolving treatment landscape, patient reliance on conventional therapies, patient's therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from Duke University Eye Center; Glaucoma Research Foundation; Centre Hospitalier National d'Ophtalmologie; European Board of Ophthalmology; Department of Ophthalmology, Kyushu University; and others.
Delveinsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps to understand and validate current and emerging therapies and treatment patterns or Glaucoma market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
Qualitative Analysis
We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.
Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.
Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
Market Access and Reimbursement
The high cost of therapies for the treatment of glaucoma is a major factor restraining the growth of the global glaucoma drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment. In the US, between 2000 and 2020, the average adjusted reimbursement for the 22 analyzed procedures decreased by 20.5%. Reimbursement is a crucial factor that affects the drug's access to the market. Market access and reimbursement options can differ depending on regulatory status, target population size, care setting, unmet need, the magnitude of incremental benefit claims, and costs.
The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.
Scope of the Report:
- The report covers a segment of key events, an executive summary, descriptive overview of Glaucoma, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
- Additionally, an all-inclusive account of the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will impact the current treatment landscape.
- A detailed review of the Glaucoma market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind the approach is included in the report covering the 7MM drug outreach.
- The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preference that help shape and drive the 7MM Glaucoma market.
Glaucoma Report Insights
- Patient Population
- Therapeutic Approaches
- Glaucoma Pipeline Analysis
- Glaucoma Market Size and Trends
- Existing and Future Market Opportunity
Glaucoma Report Key Strengths
- Twelve Years Forecast
- The 7MM Coverage
- Glaucoma Epidemiology Segmentation
- Key Cross Competition
- Attribute Analysis
- Drugs Uptake and Key Market Forecast Assumptions
Glaucoma Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Qualitative Analysis (SWOT and Conjoint Analysis)
Key Questions:
Market Insights
- What was the Glaucoma total market size, the market size by therapies, and market share (%) distribution in 2020, and how would it all look in 2034? What are the contributing factors for this growth?
- What unmet needs are associated with the current treatment market of Glaucoma?
- What will be the impact of the XELPROS patent expiry in the market?
- How will OMLONTI compete with the existing therapies for Glaucoma during the study period?
- Which drug is going to be the largest contributor in 2034?
- What are the pricing variations among different geographies for approved and off-label therapies?
- How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights
- What are the disease risk, burdens, and unmet needs of Glaucoma? What will be the growth opportunities across the 7MM concerning the patient population of Glaucoma?
- What is the historical and forecasted Glaucoma patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
- Why do only limited patients appear for diagnosis?
- Which type of Glaucoma is more prevalent and why?
- What factors are affecting the diagnosis of the indication?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies
- What are the current options for treating Glaucoma? What are the current guidelines for treating Glaucoma in the US and Europe?
- How many companies are developing therapies for treating Glaucoma?
- How many emerging therapies are in the mid-stage and late stage of development for treating Glaucoma?
- What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
- What are the key designations that have been granted for the emerging therapies for Glaucoma?
- What is the cost burden of approved therapies on the patient?
- Patient acceptability in terms of preferred treatment options as per real-world scenarios?
- What are the country-specific accessibility issues of expensive, recently approved therapies? Focus on reimbursement policies.
- What are the 7MM historical and forecasted markets of Glaucoma?
Reasons to Buy:
- The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Glaucoma Market.
- Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
- Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
- Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
- Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
- Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
- To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
- Detailed insights on the unmet need of the existing market so that the upcoming players can strengthen their development and launch strategy.
Table of Contents
1. Key Insights
2. Report Introduction
3. Country-wise Glaucoma Market Overview at a Glance
- 3.1. Country-wise Market Share (%) Distribution of Glaucoma in 2020
- 3.2. Country-wise Market Share (%) Distribution of Glaucoma in 2034
4. Glaucoma Market Overview by Class
- 4.1. Market Share (%) Distribution of Glaucoma by Class in 2020
- 4.2. Market Share (%) Distribution of Glaucoma by Class in 2034
5. Methodology of Glaucoma Epidemiology and Market
6. Executive Summary of Glaucoma
7. Key Events
8. Disease Background and Overview of Glaucoma
- 8.1. Introduction
- 8.2. Classification of Glaucoma
- 8.3. Signs and Symptoms of Glaucoma
- 8.4. Genes Involved in Glaucoma
- 8.5. Diagnosis
- 8.5.1. Diagnostic Algorithm
- 8.5.2. Diagnostic Guidelines
- 8.5.2.1. Primary Glaucoma Preferred Practice Pattern Guidelines
- 8.5.2.2. European Glaucoma Society Terminology and Guidelines for Glaucoma, 5th Edition
- 8.5.2.3. National Institute for Health and Care Excellence (NICE) Guidelines for Glaucoma diagnosis
- 8.6. Treatment and Management of Glaucoma
- 8.6.1. Treatment Algorithm
- 8.6.2. Treatment and Management Guidelines
- 8.6.2.1. International Council of Ophthalmology Guidelines for Glaucoma Eye Care
- 8.6.2.2. Level of Evidence and Recommendation in Medical Treatment of PACG
- 8.6.2.3. European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition - Chapter 3: Treatment Principles and Options Supported by the EGS Foundation
- 8.6.2.4. Primary Open-angle Glaucoma Preferred Practice Pattern guidelines
- 8.6.2.5. National Institute for Health and Care Excellence (NICE) Guidelines for Glaucoma Management
- 8.6.2.6. Optometric Clinical Practice Guideline Care of the Patient With Open Angle Glaucoma: American Optometric Association
9. Epidemiology and Patient Population
- 9.1. Key Findings
- 9.2. Assumptions and Rationale: The 7MM
- 9.2.1. Diagnosed Prevalent Cases of Glaucoma
- 9.2.2. Type-specific Diagnosed Prevalent Cases
- 9.2.3. Gender-specific Diagnosed Prevalent Cases of Glaucoma
- 9.2.4. Age-specific Diagnosed Prevalent Cases of Glaucoma
- 9.3. Total Prevalent Cases of Glaucoma in the 7MM
- 9.4. Total Diagnosed Prevalent Cases of Glaucoma in the 7MM
- 9.5. The United States
- 9.5.1. Total prevalent Cases of Glaucoma in the US
- 9.5.2. Total diagnosed prevalent cases of Glaucoma in the US
- 9.5.3. Type-specific Diagnosed Prevalent Cases of Glaucoma in the US
- 9.5.4. Type-specific Diagnosed Prevalent Cases of Open-angle Glaucoma in the US
- 9.5.5. Gender-specific Diagnosed Prevalent Cases of Glaucoma in the US
- 9.5.6. Age-specific Diagnosed Prevalent Cases of Glaucoma in the US
- 9.6. EU4 and the UK
- 9.6.1. Total Prevalent Cases of Glaucoma in EU4 and the UK
- 9.6.2. Total Diagnosed Prevalent Cases of Glaucoma in EU4 and the UK
- 9.6.3. Type-specific Diagnosed Prevalent Cases of Glaucoma in EU4 and the UK
- 9.6.4. Type-specific Diagnosed Prevalent Cases of Open-angle Glaucoma in EU4 and the UK
- 9.6.5. Gender-specific Diagnosed Prevalent Cases of Glaucoma in EU4 and the UK
- 9.6.6. Age-specific Diagnosed Prevalent Cases of Glaucoma in EU4 and the UK
- 9.7. Japan
- 9.7.1. Total prevalent cases of Glaucoma in Japan
- 9.7.2. Total diagnosed prevalent cases of Glaucoma in Japan
- 9.7.3. Type-specific Diagnosed Prevalent Cases of Glaucoma in Japan
- 9.7.4. Type-specific Diagnosed Prevalent Cases of Open-angle Glaucoma in Japan
- 9.7.5. Gender-specific Diagnosed Prevalent Cases of Glaucoma in Japan
- 9.7.6. Age-specific Diagnosed Prevalent Cases of Glaucoma in Japan
10. Patient Journey
11. Marketed Therapies
- 11.1. Key Cross Competition
- 11.2. OMLONTI/ EYBELIS (omidenepag isopropyl): Santen Pharmaceutical/Ube Industries
- 11.2.1. Product Description
- 11.2.2. Regulatory Milestones
- 11.2.3. Other Developmental Activities
- 11.2.4. Clinical Development
- 11.2.5. Clinical Trials Information
- 11.2.6. Safety and Efficacy
- 11.2.7. Product Profile
- 11.3. IYUZEH (latanoprost, 0.005%): Thea Pharma, Inc.
- 11.3.1. Product Description
- 11.3.2. Regulatory Milestones
- 11.3.3. Other Developmental Activities
- 11.3.4. Safety and Efficacy
- 11.3.5. Product Profile
- 11.4. GLA-ALPHA (ripasudil hydrochloride hydrate/brimonidine tartrate): Kowa Company/D. Western Therapeutics Institute
- 11.4.1. Product Description
- 11.4.2. Regulatory Milestone
- 11.4.3. Other Developmental Activities
- 11.4.4. Clinical Development
- 11.4.5. Clinical Trials Information
- 11.4.6. Safety and Efficacy
- 11.4.7. Product Profile
- 11.5. DURYSTA (bimatoprost SR): AbbVie Inc.
- 11.5.1. Product Description
- 11.5.2. Regulatory Milestones
- 11.5.3. Other Developmental Activities
- 11.5.4. Clinical Development
- 11.5.5. Clinical Trials Information
- 11.5.6. Safety and Efficacy
- 11.5.7. Product Profile
- 11.6. VYZULTA (latanoprostene bunod): Bausch and Lomb
- 11.6.1. Product Description
- 11.6.2. Regulatory Milestones
- 11.6.3. Other Developmental Activities
- 11.6.4. Clinical Development
- 11.6.5. Clinical Trials Information
- 11.6.6. Safety and Efficacy
- 11.6.7. Product Profile
- 11.7. XELPROS (latanoprost ophthalmic emulsion) 0.005%: Sun Pharma Advanced Research Company Limited
- 11.7.1. Product Description
- 11.7.2. Regulatory Milestones
- 11.7.3. Other Developmental Activities
- 11.7.4. Safety and Efficacy
- 11.7.5. Product Profile
- 11.8. SIMBRINZA (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%: Alcon
- 11.8.1. Product Description
- 11.8.2. Regulatory Milestones
- 11.8.3. Other Developmental Activities
- 11.8.4. Clinical Development
- 11.8.5. Clinical Trials Information
- 11.8.6. Safety and Efficacy
- 11.8.7. Product Profile
- 11.9. RHOPRESSA/RHOKIINSA (netarsudil, 0.02%): Aerie Pharmaceuticals
- 11.9.1. Product Description
- 11.9.2. Regulatory Milestones
- 11.9.3. Other Developmental Activities
- 11.9.4. Clinical Development
- 11.9.5. Clinical Trials Information
- 11.9.6. Safety and Efficacy
- 11.9.7. Product Profile
- 11.1. ROCKLATAN/ROCLANDA(netarsudil/latanoprost, 0.02%/0.005): Aerie Pharmaceuticals
- 11.10.1. Product Description
- 11.10.2. Regulatory Milestones
- 11.10.3. Other Developmental Activities
- 11.10.4. Clinical Development
- 11.10.5. Clinical Trials Information
- 11.10.6. Safety and Efficacy
- 11.10.7. Product Profile
- 11.11. GLANATEC (ripasudil): D. Western Therapeutics Institute (DWTI)/Kowa Ltd.
- 11.11.1. Product Description
- 11.11.2. Regulatory Milestones
- 11.11.3. Clinical Development
- 11.11.4. Clinical Trials Information
- 11.11.5. Safety and Efficacy
- 11.11.6. Product Profile
- 11.12. TAPTIQOM/TAPCOM (tafluprost/timolol maleate): Santen Pharmaceutical Co., Ltd.
- 11.12.1. Product Description
- 11.12.2. Regulatory Milestones
- 11.12.3. Other Developmental Activities
- 11.12.4. Clinical Development
- 11.12.5. Clinical Trials Information
- 11.12.6. Safety and Efficacy
- 11.12.7. Product Profile
- 11.13. TRAVATAN/TRAVATAN Z (travoprost, 0.004%): Novartis
- 11.13.1. Product Description
- 11.13.2. Regulatory Milestones
- 11.13.3. Other Developmental Activities
- 11.13.4. Clinical Development
- 11.13.5. Clinical Trials Information
- 11.13.6. Safety and Efficacy
- 11.13.7. Product Profile
- 11.14. LUMIGAN 0.01% (bimatoprost ophthalmic solution): Allergan/AbbVie
- 11.14.1. Product Description
- 11.14.2. Regulatory Milestones
- 11.14.3. Other Developmental Activities
- 11.14.4. Clinical Development
- 11.14.5. Clinical Trials Information
- 11.14.6. Safety and Efficacy
- 11.14.7. Product Profile
- 11.15. AILAMIDE (brimonidine tartrate/brinzolamide): Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd.
- 11.15.1. Product Description
- 11.15.2. Regulatory Milestones
- 11.15.3. Other Developmental Activities
- 11.15.4. Clinical Development
- 11.15.5. Product Profile
- 11.16. AIBETA (brimonidine tartrate/timolol maleate): Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd.
- 11.16.1. Product Description
- 11.16.2. Regulatory Milestones
- 11.16.3. Other Developmental Activities
- 11.16.4. Clinical Development
- 11.16.5. Product Profile
- 11.17. ZIOPTAN (tafluprost): Merck & Co
- 11.17.1. Product Description
- 11.17.2. Regulatory Milestones
- 11.17.3. Other Developmental Activities
- 11.17.4. Clinical Development
- 11.17.5. Clinical Trials Information
- 11.17.6. Safety and Efficacy
- 11.17.7. Product Profile
- 11.18. DuoTrav PQ (travoprost/timolol): Novartis/Alcon Research
- 11.18.1. Product Description
- 11.18.2. Regulatory Milestones
- 11.18.3. Other Developmental Activities
- 11.18.4. Clinical Development
- 11.18.5. Clinical Trials Information
- 11.18.6. Safety and Efficacy
- 11.18.7. Product Profile
- 11.19. iDose TR (travoprost intracameral implant): Glaukos Corporation
- 11.19.1. Product Description
- 11.19.2. Regulatory Milestones
- 11.19.3. Clinical Development
- 11.19.4. Clinical Trials Information
- 11.19.5. Safety and Efficacy
- 11.19.6. Product Profile
- 11.2. Catiolanze (Catioprost/DE-130A/STN1013001): Santen Pharmaceuticals
- 11.20.1. Product Description
- 11.20.2. Regulatory Milestones
- 11.20.3. Other Developmental Activities
- 11.20.4. Clinical Development
- 11.20.5. Clinical Trials Information
- 11.20.6. Safety and Efficacy
- 11.20.7. Product Profile
12. Emerging Therapies
- 12.1. Key Cross Competition
- 12.2. NCX-470: Nicox Ophthalmics
- 12.2.1. Product Description
- 12.2.2. Other Developmental Activities
- 12.2.3. Clinical Development
- 12.2.4. Clinical Trials Information
- 12.2.5. Safety and Efficacy
- 12.2.6. Product Profile
- 12.2.7. Analysts' Views
- 12.3. PDP-716: Sun Pharma Advanced Research Company Limited (SPARC)/Visiox Pharma
- 12.3.1. Product Description
- 12.3.2. Other Developmental Activities
- 12.3.3. Clinical Development
- 12.3.4. Clinical Trials Information
- 12.3.5. Safety and Efficacy
- 12.3.6. Product Profile
- 12.3.7. Analysts' Views
- 12.4. TC-002 (latanoprost): TearClear
- 12.4.1. Product Description
- 12.4.2. Other Developmental Activities
- 12.4.3. Clinical Development
- 12.4.4. Clinical Trials Information
- 12.4.5. Safety and Efficacy
- 12.4.6. Product Profile
- 12.4.7. Analysts' Views
- 12.5. Sepetaprost/ONO-9054/DE-126/STN-1012600: Santen Pharmaceutical
- 12.5.1. Product Description
- 12.5.2. Other Developmental Activities
- 12.5.3. Clinical Development
- 12.5.4. Clinical Trials Information
- 12.5.5. Safety and Efficacy
- 12.5.6. Product Profile
- 12.5.7. Analysts' Views
- 12.6. Citicoline eye drops 2%: Omikron Italia S.r.l./OPIS Spain
- 12.6.1. Product Description
- 12.6.2. Clinical Development
- 12.6.3. Clinical Trials Information
- 12.6.4. Safety and Efficacy
- 12.6.5. Product Profile
- 12.6.6. Analysts' Views
- 12.7. TRS01: Tarsier Pharma
- 12.7.1. Product Description
- 12.7.2. Other Developmental Activity
- 12.7.3. Clinical Development
- 12.7.4. Clinical Trials Information
- 12.7.5. Safety and Efficacy
- 12.7.6. Product Profile
- 12.7.7. Analysts' Views
- 12.8. QLS-101: Qlaris Bio, Inc.
- 12.8.1. Product Description
- 12.8.2. Other Developmental Activities
- 12.8.3. Clinical Development
- 12.8.4. Clinical Trials Information
- 12.8.5. Safety and Efficacy
- 12.8.6. Product Profile
- 12.8.7. Analysts' Views
- 12.9. H-1337: D. Western Therapeutics Institute (DWTI)
- 12.9.1. Product Description
- 12.9.2. Other Developmental Activity
- 12.9.3. Clinical Development
- 12.9.4. Clinical Trials Information
- 12.9.5. Safety and Efficacy
- 12.9.6. Product Profile
- 12.9.7. Analysts' Views
- 12.1. LL-BMT1: MediPrint Ophthalmics (formerly Leo Lens Pharma)
- 12.10.1. Product Description
- 12.10.2. Other Developmental Activities
- 12.10.3. Clinical Development
- 12.10.4. Clinical Trials Information
- 12.10.5. Safety and Efficacy
- 12.10.6. Product Profile
- 12.10.7. Analysts' View
- 12.11. POLAT-001 (Liposomal latanoprost): Peregrine Ophthalmic
- 12.11.1. Product Description
- 12.11.2. Other Developmental Activities
- 12.11.3. Clinical Development
- 12.11.4. Clinical Trials Information
- 12.11.5. Safety and Efficacy
- 12.11.6. Product Profile
- 12.11.7. Analysts' Views
- 12.12. VVN539: VivaVision Biotech, Inc.
- 12.12.1. Product Description
- 12.12.2. Clinical Development
- 12.12.3. Clinical Trials Information
- 12.12.4. Safety and Efficacy
- 12.12.5. Product Profile
- 12.12.6. Analyst's Views
13. Glaucoma: Market Analysis
- 13.1. Key Findings
- 13.2. Key Market Forecast Assumptions
- 13.3. Market Outlook
- 13.4. Attribute Analysis
- 13.5. Market Size of Glaucoma in the 7MM
- 13.6. Total Market Size of Glaucoma by Therapies in the 7MM
- 13.7. Market Size of Glaucoma in the United States
- 13.7.1. Total Market Size of Glaucoma
- 13.7.2. Market size of Glaucoma by Therapies in the US
- 13.8. Market Size of Glaucoma in EU4 and the UK
- 13.8.1. Total Market Size of Glaucoma
- 13.8.2. Market size of Glaucoma by Therapies in EU4 and the UK
- 13.9. Market Size of Glaucoma in Japan
- 13.9.1. Total Market Size of Glaucoma
- 13.9.2. Market size of Glaucoma by Therapies in Japan
14. Key Opinion Leaders' Views
15. SWOT Analysis
16. Unmet needs
17. Market Access and Reimbursement
- 17.1. The United States
- 17.1.1. Centre for Medicare and Medicaid Services (CMS)
- 17.2. In EU4 and the UK
- 17.2.1. Germany
- 17.2.2. France
- 17.2.3. Italy
- 17.2.4. Spain
- 17.2.5. The United Kingdom
- 17.3. Japan
- 17.3.1. MHLW
18. Appendix
- 18.1. Bibliography
- 18.2. Acronyms and Abbreviations
19. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
List of Tables
- Table 1: Summary of Glaucoma Market and Epidemiology (2020-2034)
- Table 2: Key Events
- Table 3: Two Classes of POAG Mutations
- Table 4: Genes associated with the risk of POAG
- Table 5: Genes Identified in Linkage or Association With PACG
- Table 6: Clinical Findings That Define Patients Seen With Angle-closure Disease
- Table 7: Differential Diagnosis for Glaucoma
- Table 8: The Definitions and Levels of Evidence to Rate Individual Studies
- Table 9: Recommendations for Care are Formed Based on the Body of the Evidence. The Body of Evidence Quality Ratings are Defined by GRADE
- Table 10: POAG Preferred Practice Pattern Guidelines
- Table 11: Primary Closed-angle Glaucoma Preferred Practice Pattern Guidelines
- Table 12: Time to Next Assessment for People With Suspected COAG
- Table 13: Time to Next Assessment for People With COAG
- Table 14: Initiating Open-angle Glaucoma Care - International Recommendations
- Table 15: Medicines for Glaucoma Care: International Recommendations
- Table 16: Initiating Closed-angle Care - International Recommendations
- Table 17: Unstable Closed-angle Glaucoma - International Recommendations
- Table 18: Level of Evidence and Recommendation in Medical Treatment of PACG
- Table 19: Level of Evidence and Recommendation in Treatment Laser del PACG
- Table 20: Level of Evidence and Recommendation in the Surgical Treatment of PACG
- Table 21: Total Prevalent Cases of Glaucoma in the 7MM in 000's (2020-2034)
- Table 22: Total Diagnosed Prevalent Cases of Glaucoma in the 7MM in 000's (2020-2034)
- Table 23: Total Prevalent Cases of Glaucoma in the US (2020-2034)
- Table 24: Total Diagnosed Prevalent Cases of Glaucoma in the US in 000's (2020-2034)
- Table 25: Type-specific Diagnosed Prevalent Cases of Glaucoma in the US in 000's (2020-2034)
- Table 26: Type-specific Diagnosed Prevalent Cases of Open-angle Glaucoma in the US in 000's (2020-2034)
- Table 27: Gender-specific Diagnosed Prevalent Cases of Glaucoma in the US in 000's (2020-2034)
- Table 28: Age-specific Diagnosed Prevalent Cases of Glaucoma in the US in 000's (2020-2034)
- Table 29: Total Prevalent Cases of Glaucoma in EU4 and the UK in 000's (2020-2034)
- Table 30: Total Diagnosed Prevalent Cases of Glaucoma in EU4 and the UK in 000's (2020-2034)
- Table 31: Type-specific Diagnosed Prevalent Cases of Glaucoma in Germany in 000's (2020-2034)
- Table 32: Type-specific Diagnosed Prevalent Cases of Glaucoma in France in 000's (2020-2034)
- Table 33: Type-specific Diagnosed Prevalent Cases of Glaucoma in Italy in 000's (2020-2034)
- Table 34: Type-specific Diagnosed Prevalent Cases of Glaucoma in Spain in 000's (2020-2034)
- Table 35: Type-specific Diagnosed Prevalent Cases of Glaucoma in the UK in 000's (2020-2034)
- Table 36: Type-specific Diagnosed Prevalent Cases of Glaucoma in EU4 and the UK in 000's (2020-2034)
- Table 37: Type-specific Diagnosed Prevalent Cases of Open-angle Glaucoma in Germany in 000's (2020-2034)
- Table 38: Type-specific Diagnosed Prevalent Cases of Open-angle Glaucoma in France in 000's (2020-2034)
- Table 39: Type-specific Diagnosed Prevalent Cases of Open-angle Glaucoma in Italy in 000's (2020-2034)
- Table 40: Type-specific Diagnosed Prevalent Cases of Open-angle Glaucoma in Spain in 000's (2020-2034)
- Table 41: Type-specific Diagnosed Prevalent Cases of Open-angle Glaucoma in the UK in 000's (2020-2034)
- Table 42: Type-specific Diagnosed Prevalent Cases of Open-angle Glaucoma in EU4 and the UK in 000's (2020-2034)
- Table 43: Gender-specific Diagnosed Prevalent Cases of Glaucoma in Germany in 000's (2020-2034)
- Table 44: Gender-specific Diagnosed Prevalent Cases of Glaucoma in France in 000's (2020-2034)
- Table 45: Gender-specific Diagnosed Prevalent Cases of Glaucoma in Italy in 000's (2020-2034)
- Table 46: Gender-specific Diagnosed Prevalent Cases of Glaucoma in Spain in 000's (2020-2034)
- Table 47: Gender-specific Diagnosed Prevalent Cases of Glaucoma in the UK in 000's (2020-2034)
- Table 48: Gender-specific Diagnosed Prevalent Cases of Glaucoma in EU4 and the UK in 000's (2020-2034)
- Table 49: Age-specific Diagnosed Prevalent Cases of Glaucoma in Germany in 000's (2020-2034)
- Table 50: Age-specific Diagnosed Prevalent Cases of Glaucoma in France in 000's (2020-2034)
- Table 51: Age-specific Diagnosed Prevalent Cases of Glaucoma in Italy in 000's (2020-2034)
- Table 52: Age-specific Diagnosed Prevalent Cases of Glaucoma in Spain in 000's (2020-2034)
- Table 53: Age-specific Diagnosed Prevalent Cases of Glaucoma in the UK in 000's (2020-2034)
- Table 54: Age-specific Diagnosed Prevalent Cases of Glaucoma in EU4 and the UK in 000's (2020-2034)
- Table 55: Total Prevalent Cases of Glaucoma in the US in 000's (2020-2034)
- Table 56: Total Diagnosed Prevalent Cases of Glaucoma in the Japan in 000's (2020-2034)
- Table 57: Type-specific Diagnosed Prevalent Cases of Glaucoma in Japan in 000's (2020-2034)
- Table 58: Type-specific Diagnosed Prevalent Cases of Open-angle Glaucoma in Japan in 000's (2020-2034)
- Table 59: Gender-specific Diagnosed Prevalent Cases of Glaucoma in Japan in 000's (2020-2034)
- Table 60: Age-specific Diagnosed Prevalent Cases of Glaucoma in Japan in 000's (2020-2034)
- Table 61: Key Cross Competition - Marketed drugs
- Table 62: EYBELIS (DE-117), Clinical Trial Description, 2024
- Table 63: K-232, Clinical Trial Description, 2024
- Table 64: DURYSTA (bimatoprost SR), Clinical Trial Description, 2024
- Table 65: VYZULTA (latanoprostene bunod), Clinical Trial Description, 2024
- Table 66: SIMBRINZA (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%, Clinical Trial Description, 2024
- Table 67: RHOPRESSA (netarsudil, 0.02%), Clinical Trial Description, 2024
- Table 68: ROCKLATAN (netarsudil/latanoprost 0.02%/0.005%), Clinical Trial Description, 2024
- Table 69: GLANATEC, Clinical Trial Description, 2024
- Table 70: TAPCOM/DE-111(tafluprost/timolol maleate); Clinical Trial Description, 2024
- Table 71: TRAVATAN Z (travoprost ophthalmic solution) 0.004%, Clinical Trial Description, 2024
- Table 72: LUMIGAN (bimatoprost, 0.01%), Clinical Trial Description, 2024
- Table 73: ZIOPTAN (Tafluprost), Clinical Trial Description, 2024
- Table 74: DuoTrav, Clinical Trial Description, 2024
- Table 75: iDose TR (Travoprost Intraocular Implant), Clinical Trial Description, 2024
- Table 76: DE-130A (Catioprost), Clinical Trial Description, 2024
- Table 77: Comparison of Emerging Drugs
- Table 78: NCX 470, Clinical Trial Description, 2024
- Table 79: PDP-716 (Brimonidine Tartrate Ophthalmic Suspension), Clinical Trial Description, 2024
- Table 80: TC-002 (Latanoprost ophthalmic solution), Clinical Trial Description, 2024
- Table 81: Sepetaprost (DE-126/ STN1012600), Clinical Trial Description, 2024
- Table 82: Citicoline eye drops 2%, Clinical Trial Description, 2024
- Table 83: TRS01, Clinical Trial Description, 2024
- Table 84: QLS-101, Clinical Trial Description, 2024
- Table 85: H-1337, Clinical Trial Description, 2024
- Table 86: LL-BMT1, Clinical Trial Description, 2024
- Table 87: POLAT-001, Clinical Trial Description, 2024
- Table 88: VVN539, Clinical Trial Description, 2024
- Table 89: Key Market Forecast Assumptions for Citicoline eye drops 2%
- Table 90: Key Market Forecast Assumptions for Sepetaprost (STN1012600/DE-126)
- Table 91: Key Market Forecast Assumptions for NCX 470
- Table 92: Key Market Forecast Assumptions for TRS01
- Table 93: Key Market Forecast Assumptions for PDP-716
- Table 94: Key Market Forecast Assumptions for H-1337
- Table 95: Key Market Forecast Assumptions for LL-BMT1
- Table 96: Key Market Forecast Assumptions for VVN539
- Table 97: Key Market Forecast Assumptions for Rhopressa/Rhokiinsa
- Table 98: Currently Prescribed Classes and Their Side-effects
- Table 99: Drugs in Emerging Pipeline
- Table 100: Total Market Size of Glaucoma in the 7MM, in USD million (2020-2034)
- Table 101: Market Size of Glaucoma by Therapies in the 7MM, in USD million (2020-2034)
- Table 102: Market Size of Glaucoma in the US, in USD million (2020-2034)
- Table 103: Market Size of Glaucoma by Therapies in the US, in USD million (2020-2034)
- Table 104: Market Size of Glaucoma in EU4 and the UK, in USD million (2020-2034)
- Table 105: Market Size of Glaucoma by Therapies in Germany, in USD million (2020-2034)
- Table 106: Market Size of Glaucoma by Therapies in France, in USD million (2020-2034)
- Table 107: Market Size of Glaucoma by Therapies in Italy, in USD million (2020-2034)
- Table 108: Market Size of Glaucoma by Therapies in Spain, in USD million (2020-2034)
- Table 109: Market Size of Glaucoma by Therapies in the UK, in USD million (2020-2034)
- Table 110: Market Size of Glaucoma by Therapies in EU4 and the UK, in USD million (2020-2034)
- Table 111: Market Size of Glaucoma in Japan, in USD million (2020-2034)
- Table 112: Market Size of Glaucoma by Therapies in Japan, in USD million (2020-2034)
List of Figures
- Figure 1: Classification of Glaucoma
- Figure 2: Classification of OAG
- Figure 3: Classification of OAG
- Figure 4: Risk Factors Associated With POAG
- Figure 5: Classification of Close-angle Glaucoma
- Figure 6: Symptoms of OAG
- Figure 7: Symptoms of Closed-angle Glaucoma
- Figure 8: Proposed Pathways for Normal Secretion of Myocilin Into the Aqueous Humor and for Secretion Reduced by an MYOC Mutation
- Figure 9: Diagnosis of Glaucoma
- Figure 10: Glaucoma Assessment (Optic Nerve)
- Figure 11: Evaluation of a glaucoma suspect (OAG)
- Figure 12: Treatment of Glaucoma
- Figure 13: Treatment Algorithm for Open-angle Glaucoma
- Figure 14: Treatment of Primary Open-angle Glaucoma
- Figure 15: Total Prevalent Cases of Glaucoma in the 7MM in 000's (2020-2034)
- Figure 16: Total Diagnosed Prevalent Cases of Glaucoma in the 7MM in 000'S (2020-2034)
- Figure 17: Total Prevalent Cases of Glaucoma in the US in 000's (2020-2034)
- Figure 18: Total Diagnosed Prevalent Cases of Glaucoma in the US in 000's (2020-2034)
- Figure 19: Type-specific Diagnosed Prevalent Cases of Glaucoma in the US in 000's (2020-2034)
- Figure 20: Type-specific Diagnosed Prevalent Cases of Open-angle Glaucoma in the US in 000'S (2020-2034)
- Figure 21: Gender-specific Diagnosed Prevalent Cases of Glaucoma in the US in 000's (2020-2034)
- Figure 22: Age-specific Diagnosed Prevalent Cases of Glaucoma in the US in 000's (2020-2034)
- Figure 23: Total Prevalent Cases of Glaucoma in EU4 and the UK in 000's (2020-2034)
- Figure 24: Total Diagnosed Prevalent Cases of Glaucoma in EU4 and the UK in 000's (2020-2034)
- Figure 25: Type-specific Diagnosed Prevalent Cases of Glaucoma in EU4 and the UK in 000's (2020-2034)
- Figure 26: Type-specific Diagnosed Prevalent Cases of Open-angle Glaucoma in EU4 and the UK in 000's (2020-2034)
- Figure 27: Gender-specific Diagnosed Prevalent Cases of Glaucoma in EU4 and the UK in 000's (2020-2034)
- Figure 28: Age-specific Diagnosed Prevalent Cases of Glaucoma in EU4 and the UK in 000's (2020-2034)
- Figure 29: Total Prevalent Cases of Glaucoma in Japan in 000's (2020-2034)
- Figure 30: Total Diagnosed Prevalent Cases of Glaucoma in Japan in 000's (2020-2034)
- Figure 31: Type-specific Diagnosed Prevalent Cases of Glaucoma in Japan in 000's (2020-2034)
- Figure 32: Type-specific Diagnosed Prevalent Cases of Open-angle Glaucoma in Japan in 000's (2020-2034)
- Figure 33: Gender-specific Diagnosed Prevalent Cases of Glaucoma in Japan in 000's (2020-2034)
- Figure 34: Age-specific Diagnosed Prevalent Cases of Glaucoma in Japan in 000's (2020-2034)
- Figure 35: Patient Journey of Glaucoma
- Figure 36: Primary Endpoint of DE-130A
- Figure 37: Secondary Endpoint of DE-130A
- Figure 38: Total Market Size of Glaucoma in the 7MM, in USD million (2020-2034)
- Figure 39: Total Market Size of Glaucoma in the 7MM by Therapies, in USD million (2020-2034)
- Figure 40: Market Size of Glaucoma in the US, in USD million (2020-2034)
- Figure 41: Total Market Size of Glaucoma by Therapies in the US, in USD million (2020-2034)
- Figure 42: Market Size of Glaucoma in EU4 and the UK, in USD million (2020-2034)
- Figure 43: Total Market Size of Glaucoma by Therapies in EU4 and the UK, in USD million (2020-2034)
- Figure 44: Market Size of Glaucoma in Japan, in USD million (2020-2034)
- Figure 45: Total Market Size of Glaucoma by Therapies in Japan, in USD million (2020-2034)
- Figure 46: Unmet Needs
- Figure 47: Health Technology Assessment
- Figure 48: Reimbursement Process in Germany
- Figure 49: Reimbursement Process in France
- Figure 50: Reimbursement Process in Spain
- Figure 51: Reimbursement Process in the United Kingdom
- Figure 52: Reimbursement Process in Japan
